Novo Nordisk launches weight loss drug ‘Wegovy' in India
Danish pharmaceutical company, Novo Nordisk, launched its much-awaited weight loss drug 'Wegovy' in India on Tuesday. India has the third highest number of people living with overweight and obesity. (Representational image)
One-weekly injectable semaglutide, Wegovy is the first and only weight management medication in India indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular events in people living with the condition, said the company in a statement.
It is being made available in five dosing strengths with an easy-to-use pen device which does away the use of syringes; therefore, can be self-administered at home.
India has the third highest number of people living with overweight and obesity. Alarmingly, obesity is associated with over 200 diseases, including cardiovascular diseases, certain types of cancer, and type 2 diabetes.
According to the clinical trials, the drug is shown to have 20% or more weight reduction in at least 1 in 3 individuals when used along with lifestyle interventions comprising reduced calorie diet and increased physical activity. Also, a 20% reduction in the risk of major adverse cardiovascular events, such as stroke, heart attack, and cardiovascular disease related death, when used on top of standard of care in people with established cardiovascular disease and overweight or obesity. Phase-III trial was conducted in about 3500 participants in India.
'Obesity is not just a personal health concern—it is a chronic disease and a national epidemic that India cannot afford to ignore. Recognising this, we are proud to announce that we are bringing Wegovy to Indians as a transformative and evidence-based therapeutic solution with the convenience of a world-class, state-of-the-art pen device. Additionally, we have an India-specific price with the benefit of same price for the first three dosing strengths,' said Vikrant Shrotriya, managing director, Novo Nordisk India, during the launch.
According to the company statement, wegovy will be available in a once-weekly innovative pen device in five dose strengths – 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and a maintenance dosing of 2.4 mg.
The price for 0.25, 0.5, and 1 mg doses is ₹ 17345 a month, and for 1.7 and 2.4mg it is ₹ 24280 and ₹ 26050 a month respectively.
'While deciding the pricing, our aim was to ensure that the real benefit gets accrued without burning a hole in the pocket. It's being launched pan-India, and it is prescription only drug,' said Shrotriya.
The drug acts on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, improving satiety and reducing cravings for food, eventually inducing weight-loss, said the company statement. It also improves insulin resistance and has a beneficial effect on reduction of cardiometabolic events and risk factors.
'Semaglutide is the active ingredient in… Wegovy… It is indicated for weight management and reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight.'
According to the doctors, the drug needs to be taken under medical supervision only.
'Anyone prescribed the drug has to be on a weight management programme. Indications for use include a body mass index of 30 even without comorbidities, and 27 with comorbidities. Dosage will depend on patient to patient— for weightloss, the need would be for a higher dose, and lower dose would be needed for those put on weight maintenance,' said Dr Ambrish Mithal, chairman and head of endocrinology and diabetes, Max Healthcare.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Standard
3 hours ago
- Business Standard
Colgate's Oral Health Movement - 4.5 Million Screened, Interesting Insights Uncovered, Drives Dental Visits Across India
PRNewswire New Delhi [India], June 24: Colgate-Palmolive (India) Limited has been on a mission to revolutionize India's Oral Care for over eight decades, with a deep commitment to improving the nation's Oral Health. While almost 100% of households in India are using toothpaste, the adoption of optimal Oral Care behaviour continues to present an opportunity. While nearly every Indian household uses toothpaste, the opportunity to adopt optimal oral care behavior remains significant. It's about cultivating simple, inexpensive daily habits with profound, long-term health benefits. Colgate's Oral Health Movement reveals India's Oral Health Score as 2.6 out of 5, signalling the need for prioritization of Oral Care in the country. With 90%* of Indians facing dental issues and only 9% visiting a dentist regularly, it was imperative to start a dialogue and create meaningful action around this critical issue. To bridge the awareness gap that exists between current behaviour and ideal, Colgate launched the Oral Health Movement in November 2024 - An initiative that leveraged cutting-edge technology to empower millions of Indians, enabling them to screen their oral health from their mobile phones and access free dental check-ups through a network of 50,000 dentists in partnership with the Indian Dental Association (IDA). *Dental camp study by Kantar in 2019 As part of the Colgate Oral Health Movement, over 4.5 million Indians screened their Oral Health across the length and breadth of the country with participation from 18,000+ pin codes covering more than 700 districts. Further, 1/6th of them visited a dentist post-screening (IDA data), thereby reflecting how the Movement successfully nudged Indians towards further action. Additionally, the nationwide Movement has delivered actionable intelligence on India's Oral Health, highlighting key areas that require urgent attention and intervention. The findings will shape the future of Oral Care initiatives in the country. Based on user participation in Colgate's Oral Health Movement, India's average Oral Health score is 2.6 out of 5.0. The Oral Health Score provides a powerful, personalized insight into an individual's oral health by assessing the risk of cavities, gum issues, and stains. A common thread among Indians achieving higher oral health scores was their adherence to specific healthy practices. These included brushing teeth twice a day, moderating consumption of caffeine and sugary beverages, eating a healthy and nutritious diet, and avoiding tobacco. Here's a glimpse of India's oral health landscape: * 41% of individuals face a high risk of cavities, 44% are prone to gum issues and 14% report stains * 72% of Indians are at high risk for at least one oral health concern while 4% are at the risk of all three (cavities, gum problems, teeth stains) * Only 10% of 4.5 million Indians screened, got a dental health score of 5/5 The trends also vary across age groups and regions: * More than 60% of Indians above the age of 50 are at a high risk of gum-related issues * Eastern India reported the higher incidence of tooth stains, largely linked to tobacco usage * Cavities were more common in Kerala, Jharkhand, and Rajasthan, where over 50% of participants in were found at high risk * A heightened vulnerability to cavities within two key demographics: 50% of children aged 3-12 years and 72% of older adults aged over 64 years of age. These groups require particular attention and targeted preventive care * Out of the 4.5 million respondents, 24% received the lowest score of 1 To further supplement the findings and spur a discussion around the state of India's Oral Health and the path forward, Colgate also held the 'Oral Health Movement Summit' in New Delhi today, in the presence of JP Nadda, Union Minister of Health and Family Welfare, Government of India, along with other eminent voices in the Oral Care ecosystem for an insightful discourse on India's Oral Health status. Speaking at the Summit, Ms. Prabha Narasimhan, Managing Director & CEO, Colgate-Palmolive (India) Limited said, "For over 87 years, Colgate has proudly been India's most trusted oral care brand, built on a legacy of innovation and science. Optimal Oral Health is simple and affordable - Allyou need is to invest ₹2 and 2 minutes, twice a day. We recognize that oral health, though crucial, is often overlooked in overall wellness. Improving oral hygiene can also positively impact systemic diseases like diabetes, cardiovascular conditions, and respiratory infections, thus easing the burden on one's own health and the nation's healthcare infrastructure. We acknowledge the Indian government's visionary strides in healthcare policy, from the National Oral Health Program to the National Dental Commission Act. The widespread reach and impact of programs like our Colgate Bright Smiles, Bright Futures® (BSBF) have been instrumental in driving the near-universal penetration of Toothpaste across Indian households. We envision a future where oral health is prioritized through a concerted, policy-driven approach, ultimately opening doors to a healthier life for everyone. Our state-level Public-Private Partnerships (PPPs) for the Colgate Bright Smiles, Bright Futures® (BSBF) program are already paving the way, effectively collaborating with education and healthcare departments in states like Uttar Pradesh, Goa, Assam, Maharashtra, and Andhra Pradesh. This ongoing work is effectively delivering results, demonstrating the power of collective action. The Colgate Oral Health Movement (OHM) has also unveiled vital insights that will help inform the way forward to make Oral Care a part of India's overall healthcare agenda. We stand firm in our resolve to continue our mission by sustaining the momentum that has been created by the Oral Health Movement." Speaking at the summit, Shri JP Nadda, Union Minister of Health and Family Welfare and Union Minister of Chemicals and Fertilizers said, "Colgate's Oral Health Movement in partnership with IDA has transformed oral care from a neglected concern into a national priority. The movement supports the government's National Oral Health Programme launched in 2014. I thank Colgate-Palmolive India Limited for starting this movement and clocking over 4.5 million dental screenings. This initiative has not only raised awareness, but has truly helped integrate oral care into the public health conversations. It's a powerful example of how collaborations such as these, can drive impactful change for a healthier India." Colgate's Oral Health Movement was brought to life with a multi-touchpoint campaign, which ensured a wide reach. Beyond an omni-channel approach to make the QR code, leading to the AI-enabled tool accessible, the company also engaged in on-ground screenings with the Indian Railways, leading corporations, retail outlets as well as at the Mahakumbh. About Colgate Bright Smiles, Bright Futures® (BSBF) Education is absolutely vital for prevention, and our flagship Colgate Bright Smiles, Bright Futures® (BSBF) program has truly been a game-changer. In FY25 alone, BSBF reached over 8.2 million children in 25,000 schools across 11 states, actively spreading vital oral health awareness. Children learn proper brushing techniques, the importance of brushing twice daily, the need for nutritious food, and the harmful effects of tobacco and smoking. We don't do this crucial work alone. We are grateful for our partnerships with local governments that have helped us extend our reach across the country. Additionally, we collaborate with parents, teachers, NGOs, UN bodies, dental and health professionals. By combining our expertise, we accelerate progress, ensuring prevention and good oral hygiene remain top health priorities. Since its inception in the 1970s, this impactful in-school program has reached over 185 million children and their families across India. Going forward, we're committed to reaching over 10 million children year-on-year, laying the foundation for a generation that understands and prioritizes oral health from an early age. About Colgate-Palmolive (India) Limited Colgate-Palmolive is a caring, innovative growth company that is reimagining a healthier future for all people, and the planet. Colgate-Palmolive (India) Limited is the market leader in Oral Care in the country, committed to delivering sustainable, profitable growth for its shareholders, while fostering an inclusive workplace for its people. With a primary focus on science-led innovations in Oral Care & Personal Care in the Indian market, the company is recognized for its leadership and innovative efforts in advancing sustainability and community well-being. Among its recent accomplishments, the company has made significant strides in reducing plastic waste and promoting recyclability, conserving water and energy at its manufacturing facilities, empowering women with financial and digital literacy and enhancing children's oral health through the Colgate Bright Smiles, Bright Futures® program.
Time of India
5 hours ago
- Time of India
Weight-loss drug Wegovy starts at ₹17,345 in India
Mumbai: Wegovy (semaglutide), the popular weight-loss drug from Danish drug maker Novo Nordisk , is priced between '17,345 and '26,015 across dosages in India. The company announced at its launch that the easy-to-administer once-a-weekly pen-filled injectable will have the advantage of convenient dosing. The drug will be available in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg) and will be prescribed for long-term chronic weight management and reduction in risk of major adverse cardiovascular events (MACE). Vikrant Shrotriya, MD, Novo Nordisk India, said obesity is a chronic disease and a national epidemic. "Wegovy is a transformative therapeutic solution with the convenience of a world-class, state-of-the-art pen device," he noted. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Нов таблет с Android Pro 14 Murreice Купете сега Undo Ambrish Mithal, chairman and head, endocrinology and diabetes, Max Healthcare , said although the price of Wegovy is not within the reach of the Indian masses, the potential for the drug is huge. Live Events Over time, he said, the cardiovascular benefit of Wegovy 2.4 mg is an important addition to the weight loss benefits. It is clinically proven to reduce cardiac events by 20%, both in people suffering from overweight/obesity with pre-existing heart disease. The drug can be prescribed for patients with BMI over 30 and those with BMI above 27 and pre-existing co-morbidities. Bariatric surgeon Mufazzal Lakdawala told ET that weight-loss drugs are proving to be the game-changers and they have just unlocked the potential for obese patients. He said the new age weight loss drugs could potentially complement bariatric surgery for patients beyond BMI of 45-50 as a weight-loss option. Compared to Wegovy, Mounjaro's 2.5 mg and 5 mg vials, which are also given on a weekly basis, are priced at '14,000 to '17,500 for a month's dose.
Time of India
6 hours ago
- Time of India
Novo Nordisk's Wegovy debuts in India: How it works, who it's for, and how much it costs
Source: iStock In a major development for India's fast-growing anti-obesity drug market, Novo Nordisk on Tuesday officially launched Wegovy, its highly anticipated weight-loss medication, marking a direct challenge to Eli Lilly's already available Mounjaro. Wegovy will be rolled out as a once-weekly injectable, delivered via a FlexTouch pen-like device—a user-friendly, self-administered format that eliminates the need for vials or syringes. The drug is expected to be available in Indian pharmacies by the end of June 2025, according to Vikrant Shrotriya, Managing Director of Novo Nordisk India. A market ripe for disruption Novo Nordisk is betting big on India, where nearly 254 million people live with generalized obesity and 351 million with abdominal obesity. The Danish pharma giant sees India as a key market for future sales, aiming to capture a large share of the country's ₹576 crore anti-obesity drug market, which has quadrupled from ₹133 crore in 2021, according to PharmaTrac. 'Obesity is not just a personal health concern — it is a chronic disease and a national epidemic that India cannot afford to ignore,' said Shrotriya. 'We are bringing Wegovy with the convenience of a world-class, state-of-the-art pen device, and an India-specific price.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo Source: iStock How Wegovy works: Science behind the shot Wegovy contains semaglutide, a GLP-1 receptor agonist, which mimics a natural hormone responsible for regulating blood sugar, reducing appetite, delaying gastric emptying, and improving satiety. While related drugs like Ozempic are used primarily for type 2 diabetes, Wegovy is specifically approved for chronic weight management in cases of morbid obesity. The FlexTouch device allows patients to dial in their weekly dose, with four needles included in each monthly pack. The drug works on key centers of the brain that regulate hunger and food cravings, promoting weight loss while offering additional metabolic benefits. According to diabetologist Dr. V. Mohan, 'Clinical data on semaglutide demonstrates not just weight loss but also considerable improvement in cardiovascular risk factors and inflammatory markers. For Indians, where diabetes and heart disease are on the rise, access to such evidence-based therapy offers holistic benefits.' India-specific pricing for Wegovy: Full dose list With a pricing strategy tailored for the Indian market, Novo Nordisk is offering the same cost for the initial three dosing strengths: Dose Monthly Price (₹) Per Dose (₹) 0.25 mg ₹17,345 ₹4,366 0.5 mg ₹17,345 ₹4,366 1 mg ₹17,345 ₹4,366 1.75 mg ₹24,280 ₹6,070 2.4 mg ₹26,015 ₹6,503 By comparison, Mounjaro, which contains the dual-action compound tirzepatide, is priced more competitively: Source: iStock Mounjaro Dose Monthly Price (₹) 2.5 mg ₹14,000 5 mg ₹17,500 Results comparable to bariatric surgery — but with caveats Wegovy has demonstrated remarkable outcomes in clinical studies, positioning it as a breakthrough in the treatment of obesity and related conditions. Patients using the drug experienced an average weight loss of nearly 15%, with one in three shedding as much as 20% of their body weight. Beyond weight loss, Wegovy also significantly reduces the risk of major cardiovascular events such as heart attacks and strokes. The drug also had notable benefits for liver health and showed improvement in liver fibrosis. However, the benefits of Wegovy are tied closely to continued use. Discontinuation often results in weight regain, and medical experts have raised concerns about potential muscle mass loss over time, underscoring the need for long-term management and monitoring. Wegovy vs. Mounjaro: Key differences Aspect Wegovy (Semaglutide) Mounjaro (Tirzepatide) Mechanism GLP-1 receptor agonist Dual GIP and GLP-1 receptor agonist Effect Reduces appetite, delays gastric emptying Enhances insulin secretion, appetite suppression Indication Approved for weight loss Approved for diabetes, used off-label for weight loss Dosing Once a week via Flexpen Once a week via single-dose vials Price ₹17,345–₹26,015 per month ₹14,000–₹17,500 per month One step to a healthier you—join Times Health+ Yoga and feel the change
